- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10.09. | MEI Pharma leaves biotech woes behind to rebrand as crypto company | ||
| 10.09. | PMV plots ovarian cancer filing after seeing midphase data | ||
| 10.09. | Trump admin mulls 'severe restrictions' on US pharmas licensing Chinese meds: NYT | ||
| 09.09. | FDA misinterpreted efficacy data that prompted DMD rejection, Capricor claims | ||
| 09.09. | Pfizer vet takes CEO post at new, phase 3-ready regenerative medicine biotech | ||
| 09.09. | Eli Lilly invites biotechs to use its new AI platform to help develop their own drugs | ||
| 09.09. | Novartis spends $1.4B for Tourmaline and cardiovascular med that impressed in phase 2 | ||
| 08.09. | LB Pharmaceuticals aims to raise $228M-plus in IPO to fund late-stage schizophrenia study | ||
| 08.09. | After FDA rejects Saol's ultra-rare disease prospect, advocacy groups urge patients to press Congress | ||
| 08.09. | Regeneron's allergen-blocking antibodies score phase 3 wins against cat, pollen allergies | ||
| 08.09. | Dianthus' gMG prospect blooms, with phase 2 win setting up pivotal plans | ||
| 08.09. | Atom claims phase 3 win shows gout drug can beat competition in efficacy, safety | ||
| 08.09. | Rapport's seizure drug hits in phase 2, sending stock soaring | ||
| 08.09. | Takeda, Alkermes lift lid on data for rival narcolepsy hopefuls as race to market heats up | ||
| 08.09. | Junshi heralds phase 3 psoriasis win for IL-17 drug, prepares push to Chinese regulators | ||
| 05.09. | 'Several concerning observations': FDA sheds more light on reasons it rejected drugs | ||
| 05.09. | Led by ex-HI-Bio CEO, Braveheart pays $65M to challenge BMS for heart disease market | ||
| 05.09. | BioNTech's HER2 ADC beats Roche's Kadcyla in phase 3 breast cancer trial | ||
| 04.09. | FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub | ||
| 04.09. | VC Atlas lands $400M to support existing biotech portfolio | ||
| 04.09. | AC Immune cuts workforce by 30%, trims pipeline to preserve cash | ||
| 04.09. | Enveda harvests another $150M to advance nature-inspired drugs | ||
| 04.09. | Sanofi phase 3 eczema win falls short of analyst expectations | ||
| 03.09. | Amgen-Zai stomach cancer candidate takes a turn with 'attenuated' OS benefits at final phase 3 analysis | ||
| 03.09. | Gilead's Kite erodes $2.3B off-the-shelf cell therapy deal with Shoreline |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .